Product Description: Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]World Health Organization. WHO Drug Information: Volume 38[M]. World Health Organization, 2024.
CAS Number: 2923284-76-6
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Target: Interleukin Related